America's Next Security Revolution Has Begun
Built for endurance, powered by AI, and proven in the field, the K7 is redefining protection for ports, energy hubs, and cities across the nation. The rollout is already underway.
Shares Stats
| Shares Outstanding | 538,500,000 |
| Shares Float | 537,370,000 |
| Shares Short | 13,430,000 |
| Insider Holdings | 21% |
| Institution Holdings | 83.71% |
About AMGEN Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
General
| Name | AMGEN Inc |
| Ticker | AMGN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Currency | USD |
| Country | USA |
| Fiscal Year End | December |
| Full Time Employees | 28,000 |
Highlights
| Analyst Target | 317.00 |
| Market Cap | 180,929,500,000 |
| PE Ratio | 25.98 |
| PEG Ratio | 1.06 |
| EBITDA | 16,481,000,448 |
Financials
| Curr Year EPS Estimate | 21.24 |
| Next Quarter EPS Estimate | 5.08 |
| Profit Margin | 19.52% |
| Operating Margin | 28.56 |
| Return on Assets | 0.08 |
| Return on Equity | 0.82 |
| Revenue | 35.9B |
| Earnings Per Share | 12.95 |
| Revenue Per Share | 66.89 |
| Gross Profit | 25,198,000,128 |
| Quarterly Revenue Growth | 0.12 |
Valuation
| Trailing PE | 25.97 |
| Forward PE | 15.38 |
| Price/Sales (Trailing 12 Mt.) | 5.03 |
| Price/Book (Most Recent Quarter) | 18.95 |
Dividend
AMGEN Inc pays out a dividend of $9.62 per share, with a dividend yield of 2.86%.
AMGN's next dividend payment will be made to shareholders on December 12, 2025.
They pay out 119.05% of their earnings out as a dividend.
Recent Dividends
| Dec 12, 2025 | $2.38 |
| Sep 12, 2025 | $2.38 |
| Jun 6, 2025 | $2.38 |
| Mar 7, 2025 | $2.38 |
| Dec 9, 2024 | $2.25 |
| Sep 6, 2024 | $2.25 |
| Jun 7, 2024 | $2.25 |
| Mar 7, 2024 | $2.25 |
| Dec 8, 2023 | $2.13 |
IRS boosts contribution limits for 401(k) retirement plan savers
Americans will be allowed to contribute more of their money to 401(k) and similar retirement saving plans next year.
Clearmind Medicine (CMND) Stock Soars Thursday: What's Going On?
Clearmind Medicine Inc (NASDAQ:CMND) shares are trading higher on Thursday. Here's a look at what you need to know.
The K7 Is Changing the Economics of Security - Ad
$65-an-hour guards can't compete with a $15-an-hour AI machine that never sleeps. The K7 delivers nonstop protection and smarter analytics that improve with every patrol.
AutoZone's Domestic 'Do It For Me' Business Driving Market Share Gains
Goldman Sachs upgrades AutoZone to Buy after recent sell-off, highlighting double-digit domestic DIFM growth, share gains, and long-term EPS upside through FY28.
Marjorie Taylor Greene Buys Blue Chip Stock Near 52-Week Low
Marjorie Taylor Greene is known for buying multiple stocks at a time, based on recent disclosures. A new filing shows one stock bought in November.
Why Wall Street Is Piling Into the "Debasement Trade" - Ad
Wall Street has been making headlines lately for piling into a strange new money move. What they've dubbed the "Debasement Trade"... And it could affect you and your money in a MAJOR way. Dr. David Eifrig's latest warning deserves your attention.
Marjorie Taylor Greene Buys 6 Stocks: Buffett, Health Care — And This Magnificent 7 Stock
Marjorie Taylor Greene discloses buying more stocks in October. Here's a look at what she added to her portfolio.
Job Market Pessimism Among Americans Hovers At Record Highs: 'Fears of Unemployment Have Never Been This Elevated'
Job market pessimism among Americans has reached alarming levels, with a dramatic surge in fears about unemployment and job security in recent weeks.
A Low-Profile Memecoin Is Quietly Gaining Serious Momentum - Ad
While everyone's watching the big-name coins, a lesser-known memecoin is gathering speed. With unique utility, a growing user base, and strong chart signals, our research team believes this could be a breakout waiting to happen.
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.
How To Earn $500 A Month From Applied Materials Stock Ahead Of Q4 Earnings
Applied Materials, Inc. is expected to report lower quarterly earnings and revenue on Nov. 13. Analysts recommend buying with a $250 target.
Another Gold High? Here's the Move Wall Street Is Missing ... - Ad
Gold just surged past $4,200, up 45% in a year - but Sean Brodrick says $6,900 could be next. History shows when gold booms, one hidden play has delivered far bigger gains - 21x, 49x, even 1,386x. The same strategy once handed 26,000% profits. And Sean says it's back on the table now.
The Real Reason This Analyst Still Calls Nebius His Favorite Neocloud Player
Nebius Group (NASDAQ: NBIS) reported strong Q3 results, boosting capacity & revenue guidance through 2026. Analyst reiterated Buy rating.
After 50 Years of Chemo, One Biotech Could Lead the Next Cancer Breakthrough - Ad
For decades, toxic chemotherapy defined cancer care. This biotech's innovative approach could finally change that. With early results showing precision without poison, this story is one investors will want to see early.
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.
Ford Expedition vs GMC Yukon, an Edmunds big SUV comparison
Let’s say you need a vehicle with room for more than five passengers, a large cargo area, and the ability to pull a heavy trailer. A full-size three-row SUV should work well, but which one? The most significant news this year is the redesigned . Ford has given its biggest SUV a complete makeover with a more upscale interior, new technology features and a novel split-opening tailgate.
The New Gold Trade Dominating on Wall Street - Ad
Wall Street has been making headlines lately for piling into gold. According to Dr. David Eifrig, the gold bull run is just getting started. He says you should move your money to his No. 1 gold stock immediately (not a miner or ETF but it has 1,000% upside potential.)
Time To Sell XRP? These 3 Indicators Scream 'Take Profits'
XRP (CRYPTO: XRP) fell below key moving averages on Wednesday, signaling fading bullish momentum as multiple indicators flashed a strong sell warning.
Vietnam's VinFast Hits Over 20,000 Monthly EV Deliveries
VinFast delivered a record 20,380 EVs in Vietnam in October—first local maker to top 20k in a month—even as shares dipped.
Buy This Stock Tomorrow? - Ad
A renowned former hedge fund manager - friends to some of the biggest investors in the world - just released a new list of his favorite AI stocks... and not a single Magnificent 7 name made the cut. Instead, an AI stock you've likely never heard of just flagged as "near-perfect" in his new investing scoring system.
Mark Zuckerberg's Patience 'Ran Out': Hyperbolic CTO Says Yann LeCun's Meta Exit Was Inevitable After $15 Billion Alexandr Wang Deal
Hyperbolic CTO Yuchen Jin claimed that Yann LeCun's reported exit from Meta was inevitable after Mark Zuckerberg's $15 billion acquisition of Alexandr Wang, signaling a power shift in Meta's AI strategy from long-term research to aggressive, product-driven innovation.
Michael Caine and Matthew McConaughey partner with ElevenLabs for AI voice cloning
NEW YORK (AP) — Oscar-winning actors Michael Caine and Matthew McConaughey have made deals with voice-cloning company ElevenLabs that will allow its artificial intelligence technology to replicate their voices.
This Overlooked Memecoin Is Showing Early Breakout Signals - Ad
We've been tracking one small memecoin that checks all the boxes: strong on-chain signals, real traction, and an entry point that could offer serious upside. It's not on many radars yet-but that could change fast.
How Europe's private drone industry eyes opportunity as NATO strengthens defense
AALBORG, Denmark (AP) — In a warehouse more than 1,500 kilometers (900 miles) from Ukraine's capital, workers in northern Denmark painstakingly piece together . Some of the devices will be exported to Kyiv in the hopes of jamming Russian technology on the battlefield, while others will be shipped across Europe in efforts to combat mysterious drone intrusions into NATO's airspace that have the entire continent on edge.
Wall Street Enters Its Strongest Month: These 7 Stocks Often Crush It
November is historically Wall Street's strongest month. These 7 stocks often delivered standout gains in recent decades.
"Tech Prophet" Who Predicted the iPhone Now Predicts... - Ad
George Gilder - who predicted the iPhone 17 years early and gave Reagan the first microchip - is making his boldest call yet. He says an American nanotech "super-convergence" could mint more millionaires than any event in recent memory. He's found 3 stocks set to benefit before November 18's bombshell.
FDA says drugmakers have recalled a blood pressure medicine tainted with a cancer-causing chemical
The U.S. Food and Drug Administration says drugmakers have recalled more than a half-million bottles of the blood pressure medication prazosin hydrochloride over concerns it may include a cancer-causing chemical.
Court Blocks Trump's SNAP Reductions, But Stricter Eligibility Rules Begin
New work requirements for SNAP begin Saturday, but benefits may not be issued through November due to the government shutdown.
America's Next Security Revolution Has Begun - Ad
Built for endurance, powered by AI, and proven in the field, the K7 is redefining protection for ports, energy hubs, and cities across the nation. The rollout is already underway.
A medley of tech gifts for everyone on your holiday shopping list
NEW YORK (AP) — It's the most wonderful time of the year, unless you want to find the perfect gifts for .
Elon Musk Teases Two More Tesla Diner Locations After Success In California: Here Are The Future Spots
The EV company opened its first Tesla Diner in July. CEO Elon Musk hints that more locations could be coming.
The K7 Is Changing the Economics of Security - Ad
$65-an-hour guards can't compete with a $15-an-hour AI machine that never sleeps. The K7 delivers nonstop protection and smarter analytics that improve with every patrol.
Trump's White House Bathroom Renovation Sparks Fury, Economist Slams 'Clearly Wrong' Inflation Data And More: This Week In Economy
Week economy roundup: From inflation debates and White House renovations to job declines, stock surges, and Fed rate cuts.
Ford's Recall Count Climbs To 134 In 2025 — CEO Jim Farley Sees It As Biggest 'Near-Term Opportunity'
Ford has been plagued by recalls, tariffs, and quality control issues, with CEO Jim Farley optimistic about addressing them.
Why Wall Street Is Piling Into the "Debasement Trade" - Ad
Wall Street has been making headlines lately for piling into a strange new money move. What they've dubbed the "Debasement Trade"... And it could affect you and your money in a MAJOR way. Dr. David Eifrig's latest warning deserves your attention.
Trump Hits Sherrill, Boosts Ciattarelli In New Jersey
Donald Trump attacks Mikie Sherrill in NJ telerally, backs Jack Ciattarelli, sparking energy policy clashes and sharp campaign rebuttals statewide.
16 Stocks To Buy If You Want To Escape The AI Hype
Bank of America is pointing investors toward 16 overlooked stocks with strong fundamentals and no direct ties to the AI boom—offering a safer path beyond the hype.
A Low-Profile Memecoin Is Quietly Gaining Serious Momentum - Ad
While everyone's watching the big-name coins, a lesser-known memecoin is gathering speed. With unique utility, a growing user base, and strong chart signals, our research team believes this could be a breakout waiting to happen.
Golf Icon Phil Mickelson Refutes Claims Of Insider Trading Involvement, Says, 'I Make No Trades Whatsoever'
Golfer Phil Mickelson has denied allegations of insider trading linked to an offshore oil company Sable Offshore Corp.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.